Here’s what you should know:
1. Researchers developed a pancreatic cancer treatment, metavert. In mice, the drug blocked drug-resistant pancreatic ductal adenocarcinomas, while boosting radiation’s positive effects.
2. Metavert did not impact non-transformed cells.
3. Metavert boosted mouse survival rate, while decreasing tumor infiltration and blood levels.
In an article with Daily Science, lead study author Mouad Edderkaoui, PhD, said, “This is an exciting step toward improving survival rates in pancreatic cancer patients. If the results are confirmed in humans, we could have a drug with the potential to significantly extend the lives of patients with pancreatic ductal adenocarcinoma, which is very difficult to treat.”
More articles ongastroenterology:
An Inside Look at the Future of GI EHR Systems
GI leader to know: Dr. Allan Coates of Gastroenterology Associates of Western Michigan
How Boston Scientific’s outreach program is helping beat CRC
